A high throughput MHC II binding assay for quantitative analysis of peptide epitopes.

Biochemical assays with recombinant human MHC II molecules can provide rapid, quantitative insights into immunogenic epitope identification, deletion, or design(1,2). Here, a peptide-MHC II binding assay is scaled to 384-well format. The scaled down protocol reduces reagent costs by 75% and is higher throughput than previously described 96-well protocols(1,3-5). Specifically, the experimental design permits robust and reproducible analysis of up to 15 peptides against one MHC II allele per 384-well ELISA plate. Using a single liquid handling robot, this method allows one researcher to analyze approximately ninety test peptides in triplicate over a range of eight concentrations and four MHC II allele types in less than 48 hr. Others working in the fields of protein deimmunization or vaccine design and development may find the protocol to be useful in facilitating their own work. In particular, the step-by-step instructions and the visual format of JoVE should allow other users to quickly and easily establish this methodology in their own labs.

[1]  W. Martin,et al.  De-immunization of therapeutic proteins by T-cell epitope modification. , 2005, Developments in biologicals.

[2]  R. Rappuoli,et al.  Developing vaccines in the era of genomics: a decade of reverse vaccinology. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  A. D. De Groot,et al.  Harnessing the power of genomics and immunoinformatics to produce improved vaccines , 2011, Expert opinion on drug discovery.

[4]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[5]  Chris Bailey-Kellogg,et al.  Structure‐based redesign of proteins for minimal T‐cell epitope content , 2013, J. Comput. Chem..

[6]  G. Li Pira,et al.  High Throughput T Epitope Mapping and Vaccine Development , 2010, Journal of biomedicine & biotechnology.

[7]  Julie A McMurry,et al.  In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. , 2009, Vaccine.

[8]  Anne S De Groot,et al.  Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. , 2009, Clinical immunology.

[9]  Chris Bailey-Kellogg,et al.  Open Access Methodology Article Optimization Algorithms for Functional Deimmunization of Therapeutic Proteins , 2022 .

[10]  Ira Mellman,et al.  Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.

[11]  O. Lund,et al.  NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure , 2010, Immunome research.

[12]  William W. Kwok,et al.  Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide , 2006, The Journal of experimental medicine.

[13]  L Raddrizzani,et al.  Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. , 1997, Journal of immunology.

[14]  Ji Wan,et al.  SVRMHC prediction server for MHC-binding peptides , 2006, BMC Bioinformatics.

[15]  Chris Bailey-Kellogg,et al.  Structure-Guided Deimmunization of Therapeutic Proteins , 2012, RECOMB.

[16]  Søren Buus,et al.  Functional recombinant MHC class II molecules and high-throughput peptide-binding assays , 2009, Immunome research.

[17]  M. Roederer,et al.  Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. , 2005, Trends in immunology.

[18]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[19]  Chris Bailey-Kellogg,et al.  Optimization of Therapeutic proteins to Delete T-Cell epitopes while Maintaining Beneficial Residue Interactions , 2011, J. Bioinform. Comput. Biol..

[20]  Wei Jiang,et al.  High-throughput engineering and analysis of peptide binding to class II MHC , 2010, Proceedings of the National Academy of Sciences.

[21]  Biologic drugs set to top 2012 sales , 2012, Nature Medicine.

[22]  L. Picker,et al.  Mapping T cell epitopes by flow cytometry. , 2003, Methods.

[23]  Alessandro Sette,et al.  Reverse vaccinology: developing vaccines in the era of genomics. , 2010, Immunity.

[24]  Pingping Guan,et al.  MHCPred: bringing a quantitative dimension to the online prediction of MHC binding. , 2003, Applied bioinformatics.

[25]  Saurabh Aggarwal,et al.  What's fueling the biotech engine—2011 to 2012 , 2012, Nature Biotechnology.

[26]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[27]  Leonard Moise,et al.  Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. , 2012, Clinical immunology.

[28]  T. Baglin,et al.  Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII , 2005, Journal of thrombosis and haemostasis : JTH.

[29]  Morten Nielsen,et al.  Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method , 2007, BMC Bioinformatics.

[30]  Marc De Maeyer,et al.  Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer Modeling , 2002, Thrombosis and Haemostasis.

[31]  Bjoern Peters,et al.  Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications , 2005, Immunogenetics.

[32]  George Georgiou,et al.  Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift , 2011, Proceedings of the National Academy of Sciences.

[33]  Chris Bailey-Kellogg,et al.  Design and analysis of immune-evading enzymes for ADEPT therapy. , 2012, Protein engineering, design & selection : PEDS.

[34]  Ronit Mazor,et al.  Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A , 2012, Proceedings of the National Academy of Sciences.

[35]  Wolfgang Aehle,et al.  A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy , 2005, Molecular Cancer Therapeutics.